Flu cases in Scotland are expected to “spike” in the coming weeks, the health secretary has warned.
Neil Gray MSP said rates of the illness are following a similar trend…
Author: admin
-
Flu cases likely to ‘spike’ in coming weeks, warns health secretary
Neil Gray spoke to BBC Scotland’s The Sunday Show about flu cases in Scotland. -
McCullum: England ‘over-prepared’ in second Test build-up
Brendon McCullum claimed that his England team were “over-prepared” for the second Ashes Test in Brisbane and defended their planned trip to the resort town of Noosa before travelling to Adelaide.
England trained five times – once at Allan Border…
Continue Reading
-
What we learned from the ISU Grand Prix Final 2025
Which women will emerge from Japan?
Surging 17-year-old Nakai Ami won silver in her Grand Prix Final debut, amid her rookie senior season. Three-time world champion Sakamoto Kaori bounced back from a forgettable short program to secure bronze,…
Continue Reading
-
KLEVV CRAS V RGB 48 GB DDR5-9600 CL36 Memory Review: Extremely Fast!
Product Info KLEVV CRAS V RGB DDR5 9600 48 GB
December, 2025
Type
Memory Kit
Price
TBD
The DDR5 memory segment has been experiencing significant activity as it becomes standardized across all…
Continue Reading
-
The Targeted Pulse: FDA Approvals, Trial Updates, and ASH 2025 Previews | Targeted Oncology
Welcome to this week’s edition of The Targeted Pulse, your weekly wrap-up of the top developments in oncology. This week, we saw FDA decisions, learned about care-changing trial data, and got a preview of the most anticipated 67th American Society of Hematology (ASH) Annual Meeting and Expositionabstracts. From regulatory designations for promising new drugs to crucial clinical trials, here are the top stories that shaped the week.
The FDA has granted premarket approval to the IsoPSA blood-based in vitro diagnostic kit, intended to aid clinicians in deciding whether to proceed with prostate biopsy. It is indicated for men aged ≥ 50 years with elevated prostate-specific antigen (PSA) levels.
Unlike traditional PSA testing, IsoPSA leverages the IsoClear™ platform to analyze structural characteristics (isoforms) of the PSA protein, offering enhanced specificity. Clinical utility is recognized by inclusion in NCCN and AUA/SUO guidelines, as it improves risk stratification for high-grade (Gleason score ≥7) prostate cancer. The test is expected to decrease unnecessary biopsies stemming from benign PSA elevations.
The phase 3 OptiTROP-Lung05 trial demonstrated that the combination of sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate [ADC], plus pembrolizumab (Keytruda) offers a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab monotherapy for first-line treatment of advanced, PD-L1-positive non–small cell lung cancer (NSCLC).
This study marks the first time an ADC combined with an immune checkpoint inhibitor has met a primary end point in the first-line NSCLC setting. The regimen also showed a positive trend in overall survival (OS) with a manageable safety profile. This combination represents a new, highly effective, and novel therapeutic option for clinicians managing these patients.
The FDA has granted traditional approval to pirtobrutinib (Jaypirca), a highly selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor, for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This indication specifically targets patients previously treated with a covalent BTK inhibitor.
The decision is based on the phase 3 BRUIN-CLL-321 trial, which showed a statistically and clinically significant PFS benefit. Median PFS was 11.2 months (95% CI, 9.5–11.4) with pirtobrutinib vs 8.7 months (95% CI, 7.2–10.2) for investigator’s choice of therapy (HR, 0.58; P =.0105). This noncovalent agent provides a mechanism to continue BTK pathway targeting after resistance to covalent inhibitors.
The Targeted Oncology® poll highlighted several practice-changing abstracts for the 67th ASH Annual Meeting and Exposition, primarily in multiple myeloma (MM), CLL, and myelofibrosis. The most anticipated presentation is the phase 3 MajesTEC-3 trial, which evaluated the combination of the bispecific antibody teclistamab plus daratumumab (Tec-Dara) against standard-of-care regimens in relapsed/refractory MM. The data demonstrated statistically and clinically significant improvements in PFS and OS for Tec-Dara. These findings support establishing the Tec-Dara regimen as a new standard of care early in the R/R MM treatment landscape. Other highly anticipated data include primary results for pirtobrutinib in previously untreated CLL/SLL (LBA-3).
The bispecific HER2-directed ADC TQB2102 demonstrated robust activity in the phase 2 TQB2102-II-01 trial as a neoadjuvant therapy for HER2-positive breast cancer. Its novel design targets 2 non-overlapping HER2 epitopes to enhance blockade.
The 6.0 mg/kg regimen administered over 8 cycles achieved the highest total pathologic complete response rate at 76.9% (90% CI, 62.3%–87.6%). The drug exhibited a favorable safety profile, with grade 3 treatment-related adverse events occurring in 27.9% of patients across all cohorts. These compelling efficacy and safety data support the ongoing randomized phase 3 evaluation of TQB2102 against standard neoadjuvant regimens in this patient population.
Continue Reading
-
Is USA Rare Earth’s 2025 Valuation Justified After 49.9% Gain and Policy Driven Hype?
-
Wondering if USA Rare Earth is actually worth the hype at its current price, or if the story has already run ahead of the fundamentals? This breakdown is designed to give you a clear, valuation focused view.
-
USA Rare Earth has been anything but quiet lately, jumping 28.0% over the last week and climbing 39.2% year to date. This is even though the 30 day move is roughly flat at -0.8% and the 1 year gain sits at 49.9%.
-
Much of that momentum has been fueled by ongoing headlines around US efforts to secure domestic supplies of critical minerals and reduce dependence on overseas rare earth processing. As USA Rare Earth positions itself as part of that strategic supply chain, investors are starting to price in the potential upside and the risks that come with policy driven demand.
-
Right now, USA Rare Earth scores a 2/6 valuation check score. This means it screens as undervalued on 2 of our 6 metrics, and in the next sections we will unpack those traditional valuation approaches before finishing with a more holistic way to judge whether the current price really makes sense.
USA Rare Earth scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
A Discounted Cash Flow (DCF) model estimates what a business is worth today by projecting its future cash flows and discounting them back to their present value. For USA Rare Earth, this uses a 2 Stage Free Cash Flow to Equity framework.
The company is currently burning cash, with last twelve month free cash flow at around -$39.0 Million. Analyst forecasts and subsequent extrapolations see this negative cash flow deepening to roughly -$114.4 Million in 2026 before turning positive and climbing to about $438.5 Million by 2035. These later years rely on Simply Wall St extrapolations once analyst coverage runs out.
When all those projected cash flows are discounted back, the model arrives at an intrinsic value of about $40.05 per share. Compared with the current share price, this implies the stock is trading at roughly a 57.0% discount, suggesting the market is heavily discounting the long term cash flow recovery story.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests USA Rare Earth is undervalued by 57.0%. Track this in your watchlist or portfolio, or discover 907 more undervalued stocks based on cash flows.
USAR Discounted Cash Flow as at Dec 2025 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for USA Rare Earth.
For asset heavy businesses in the metals and mining space, the price to book ratio is often a useful reality check because it compares what investors are paying in the market with the accounting value of the company’s net assets. In theory, faster growth and lower risk justify a higher multiple, while slower growth or higher uncertainty should pull a fair price to book closer to, or even below, the value of the underlying assets.
Continue Reading
-
-
Sydney Sweeney says her silence over jeans advert backlash ‘widened the divide’ | Sydney Sweeney
The actor Sydney Sweeney has said she should have addressed the controversy surrounding her American Eagle jeans advert, which was accused by critics of flirting with eugenics, saying not doing so “widened the divide” between people.
Sweeney,…
Continue Reading
-
Grim Signals of Future Antimicrobial Resistance Found Lurking in Sewage : ScienceAlert
Dangerous bacteria and other disease-causing microbes are rapidly evolving ways to defy our best antibiotic medications, a phenomenon known as antimicrobial resistance. Humans are inadvertently contributing by overexposing pathogens to our…
Continue Reading
